斯皮诺素对人肝微粒体细胞色素P450酶的体外抑制作用 点击下载
论文标题: 斯皮诺素对人肝微粒体细胞色素P450酶的体外抑制作用
英文标题:
中文摘要: 目的:研究斯皮诺素对人肝微粒体细胞色素P450(CYP450)酶7种亚型(CYP2B6、CYP2C8、CYP2C9、CYP2D6、CYP1A1、CYP2C19和CYP3A4)的体外抑制作用。方法:以200.00、100.00、50.00、25.00、12.50、6.25、3.13、1.56、0.78、0.39 μmol/L的斯皮诺素与人肝微粒体共同孵育,分别以他克宁、安非他酮、盐酸阿莫地喹、双氯芬酸钠、美芬妥英、氢溴酸右美沙芬和咪达唑仑作为上述7种亚型CYP450酶的特异性探针药物。采用超高效液相色谱-四级杆-飞行时间串联质谱法测定7种探针药物的代谢产物生成量,计算斯皮诺素对人肝微粒体中7种亚型CYP450酶的半数抑制浓度(IC50)。结果:斯皮诺素对人肝微粒体7种亚型CYP450酶的IC50分别为1 714、 1 158、226.1、2 288、80.59、101.1、1 119 μmol/L,均大于50 μmol/L。结论:斯皮诺素对人肝微粒体CYP450酶的上述7种亚型均无抑制作用,引发药物代谢性相互作用的可能性较小。
英文摘要: OBJECTIVE: To study the inhibition effect of spinosin on 7 subtypes (CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP1A1, CYP2C19 and CYP3A4) of cytochrome P450 (CYP450) enzymes from human liver microsomes in vitro. METHODS: Taking 200.00, 100.00, 50.00, 25.00, 12.50, 6.25, 3.13, 1.56, 0.78, 0.39 μmol/L spinosin and human liver microsomes for incubation, using daktarin, bupropion, amodiaquine hydrochloride, diclofenac sodium, mephenytoin, dextromethorphan hydrobromide and midazolam as the specific probe drugs for above-mentioned 7 subtypes of CYP450 enzymes. UPLC-Q-TOF-MS was conducted to detect generation amount of 7 probe drug metabolites, and the half inhibitory concentration (IC50) of spinosin on 7 subtypes of CYP450 enzymes from human liver microsomes was calculated. RESULTS: IC50 of spinosin on 7 subtypes of CYP450 enzymes from human liver microsomes were 1 714, 1 158, 226.1, 2 288, 80.59, 101.1, 1 119 μmol/L, respectively, which were higher than 50 μmol/L. CONCLUSIONS: Spinosin has no inhibition effect on above-mentioned 7 subtypes of CYP450 enzymes from human liver microsomes, with very low probability of inducing metabolic drug interactions.
期刊: 2017年第28卷第19期
作者: 张巧月,刘艳艳,万昶宸,廖曼,张霞,刘天意,张兰桐
英文作者: ZHANG Qiaoyue,LIU Yanyan,WAN Changchen,LIAO Man,ZHANG Xia,LIU Tianyi,ZHANG Lantong
关键字: 斯皮诺素;超高效液相色谱-四级杆-飞行时间串联质谱法;细胞色素P450酶;抑制作用
KEYWORDS: Spinosin; UPLC-Q-TOF-MS; Cytochrome P450 enzymes; Inhibition effect
总下载数: 81次
本日下载数: 2次
本月下载数: 81次
文件大小: 619.60Kb

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!